A prospective, randomized trial to evaluate the efficacy of clean intermittent catheterization versus triamcinolone ointment and contractubex ointment of catheter following internal urethrotomy: long-term results.
OBJECTIVE
Our aim was to evaluate clean intermittent catheterization (CIC) results in combination with triamcinolone ointment and contractubex ointment for lubrication of the catheter after optical internal urethrotomy (OIU).


METHODS
Ninety patients who underwent OIU were randomized into three groups. Two weeks after operation, patients were treated with CIC (group A), triamcinolone ointment CIC (group B), and contractubex ointment CIC (group C). Follow-up continued for 24 months after the OIU. Postoperative results were compared between the three groups.


RESULTS
There were no significant differences in the baseline characteristics of the patients or the etiology of the urethral stricture between the three groups. The mean preoperative Q max was 4.31 ml/s. The average score of preoperative international prostate symptom score (IPSS) was 23.1 points. In both groups, after treatment, significant improvements in Q max and IPSS were noted at all follow-up period (p < 0.05). But for Q max and IPSS, there were not any significant differences between groups at all follow-up period (p > 0.05). Overall recurrence rate was 28.9 % (26 out of 90 patients) at the end of the study. Recurrence rates were, however, not found to be statistically significant between these three groups (p > 0.05).


CONCLUSIONS
Our results indicate that the urethral dilation protocol with CIC after first OIU is a safe, simple, well-tolerated, office-based procedure. Triamcinolone or contractubex ointments of the CIC do not provide an additional benefit. Currently, urethral dilation with CIC after first OIU seems to be the only proven procedure that decreased the recurrence rate.
Department of Urology, KonyaTraining and Research Hospital, Konya, Turkey, osmanergun77@mynet.com.
Osman
O
Ergün
Ahmet
A
Güzel
Abdullah
A
Armağan
Alim
A
Koşar
Ayşe Gül
AG
Ergün
D000328:Adult; D000368:Aged; D000481:Allantoin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004338:Drug Combinations; D005938:Glucocorticoids / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D057928:Intermittent Urethral Catheterization; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010936:Plant Extracts / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014221:Triamcinolone / Q000627:therapeutic use*; D014521:Urethra / Q000601:surgery*; D014525:Urethral Stricture / Q000628:therapy*; D013521:Urologic Surgical Procedures, Male / Q000379:methods; D055815:Young Adult
D004338:Drug Combinations; D005938:Glucocorticoids; D009824:Ointments; D010936:Plant Extracts; C053099:allantoin, heparin, onion extract drug combination; D014221:Triamcinolone; D000481:Allantoin; D006493:Heparin